Targeting of cytokine gene expression to malignant melanoma cells using tissue specific promoter sequences
- 1 September 1994
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 5 (suppl_4) , S59-S65
- https://doi.org/10.1093/annonc/5.suppl_4.s59
Abstract
Background : Transduction of turnour cells in vitro with cDNAs encoding various cytokines and/or immune accessory molecules has been shown to diminish or eliminate tumorigenicity when such cells are returned in vivo to syngeneic animals. One method being explored for in situ gene therapy is to use tissue-specific promoters to direct expression of the therapeutic genes to the tumour cells. Design : This study used the 5′ flanking region of the murine tyrosinase gene to direct expression of three different cytokine genes [murine interleukin 2 (IL-2), IL-4 and macrophage colony-stimulating factor (M-CSF)] specifically to murine melanoma cells. Results : Expression of the IL-2 gene, from 2.5 kbp of the 5′ flanking region of the murine tyrosinase gene, was detected in 11 out of 55 puromycinresistant B16 clones isolated after transfection. The highest producing clone secreted 2000 pg/ml/10 6 cells/48 hours as detennined by enzymelinked immunosorbent assay. The IL-2 was tested for biological activity by its ability to stimulate proliferation of the IL-2 dependent CTLL cell line. No detectable level of IL-2 expression occurred in 58 clones of drug-resistant NIH 3T3 by cells derived after transfection with the same construct. Similar results were obtained following transfection of these two cell lines with the tyrosinase-IL-4 minigene construct. Expression of IL-2 in the murine melanoma cells completely abrogated their tumorigenicity in syngeneic mice. However, progressively growing tumours were produced from clones in which the IL-2 gene was no longer expressed (as determined by reverse transcriptase polymerase chain reaction). Direct injection of DNA encoding cytokine genes, expressed from the tyrosinase promoter, into established B16 melanomas in syngeneic mice resulted in gene expression within the tumour mass. While no change in tumour growth was observed following such treatment, the results demonstrate that direct injection of naked DNA into a neoplasm can result in uptake and expression of cytokine genes up to 16 days post-injection. Conclusion : The use of tissue-specific promoters can limit expression to the required target cell, while the choice of appropriate gene should result in an alteration in turnour burden.Keywords
This publication has 22 references indexed in Scilit:
- Cancer vaccinesImmunology Today, 1993
- Targeted delivery of DNA for gene therapy via receptorsTrends in Biotechnology, 1993
- Targeting of Retroviral Vectors for Gene TherapyHuman Gene Therapy, 1993
- Pigmentation Genes: the Tyrosinase Gene Family and the pmel 17 Gene FamilyJournal of Investigative Dermatology, 1993
- Karnofsky Memorial Lecture. The immunotherapy and gene therapy of cancer.Journal of Clinical Oncology, 1992
- Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma: an innovative approach for cancer therapy.Proceedings of the National Academy of Sciences, 1991
- The mouse tyrosinase promoter is sufficient for expression in melanocytes and in the pigmented epithelium of the retina.Proceedings of the National Academy of Sciences, 1991
- Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor responseCell, 1990
- cDNA cloning and expression of murine macrophage colony-stimulating factor from L929 cells.Proceedings of the National Academy of Sciences, 1988
- Establishment of mouse cell lines which constitutively secrete large quantities of interleukin 2, 3, 4 or 5, using modified cDNA expression vectorsEuropean Journal of Immunology, 1988